Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2025—Adding interpretive comments in lay language to placental pathology reports helps physicians and other providers understand the reports and makes it easier for them to share the findings with patients.
April 2025—Seen through the lens of metaphor, cancer staging is traffic control. Identify the biological crash, so to speak, and its severity; direct and redirect therapy; and try, ultimately, to unsnarl persistently risky crossings. That’s the sunny ideal. But efforts to improve traffic flow can also give rise to strong reactions, usually in words (if not a chorus of honking horns). Such is the case with the updated International Federation of Gynecology and Obstetrics staging system for endometrial cancer. FIGO 2023, by nearly all accounts, differs sharply from what had come before, incorporating molecular alterations, lymphovascular invasion, and tumor type and grade. Nearly two years later, it has yet to merge seamlessly into practice. “It definitely is controversial,” says Ekene Okoye, MD, associate professor of clinical pathology and genomic medicine, Department of Pathology and Genomic Medicine, Houston Methodist Hospital and Weill Cornell Medical College.
April 2025—Unprecedented moves with a lot of moving parts is how Jessica Wang-Rodriguez, MD, of the Veterans Health Administration describes a transition to digital pathology the size of the VHA’s. It’s a mission that has become necessary, Dr. Wang-Rodriguez says of the large-scale digital pathology transformation. She is executive director of the VHA National Pathology and Laboratory Medicine Program Office, Washington, DC, and professor of pathology at the University of California, San Diego.
April 2025—Rebecca Previs, MD, MS, gynecologic oncologist and director of medical affairs at Labcorp, captures the vibe ahead of the ASCO conference next month in Chicago in just a few words. “It’s exciting,” she says. “This is unprecedented territory.” With the field undergoing “a major shift toward biology-driven rather than tissue-of-origin-driven oncology treatment,” Dr. Previs is far from the only industry representative who is optimistic about the future—though the many challenges ahead temper that excitement.
March 2025—The Ventana CLDN18 (43-14A) RxDx Assay, the companion diagnostic for zolbetuximab, detects the claudin 18 protein in formalin-fixed, paraffin-embedded gastric adenocarcinoma including gastroesophageal junction tissue specimens. Gastric intestinal metaplasia can be used as a positive tissue control and system level control and should display weak to moderate membrane staining.
March 2025—A study of oncology patients at the Medical College of Wisconsin sheds light on how they perceive the content and timing of pathology report review. The study findings were gathered through in-person and telehealth interviews with patients with breast, endocrine, gastrointestinal, genitourinary, and thoracic malignancies. Medical student Amber Y. Bo, MD, in 2022 and 2023 conducted 230 interviews with patients who had a prior opportunity to review their reports in the patient portal.
February 2025—HER2 in predictive biomarker testing, HPV-related cancer testing guidelines, and the art of applying polygenic risk scores will be some of what’s heard in USCAP 2025 sessions next month in Boston.
January 2025—Pathology informatics leaders at the University of Michigan are moving in steps to a fully digital practice as they put in place an innovative workflow for primary diagnosis. Fresh off their August launch of the new workflow program within their remodeled histology lab, informatics directors in the pathology department say Michigan Medicine is the first in the U.S. to have radiology and pathology operating in the same shared picture archiving and communication system, or PACS, and to implement the well-established DICOM standard for pathology workflow.
January 2025—Whether grade group 1 prostate cancer should be renamed to “noncancer” was the center of debate on a CAP podcast last fall led by Gladell P. Paner, MD, in discussion with Ming Zhou, MD, PhD, and Rajal B. Shah, MD. Dr. Paner is professor of pathology and surgery, University of Chicago Pritzker School of Medicine, and director of the genitourinary pathology service and of the reproductive endocrinology and infertility laboratory, UChicago Medicine.
December 2024—Digital pathology in 2024—what’s the sentiment, the pace, the holdup, the worry? Five people spoke online with CAP TODAY publisher Bob McGonnagle on Oct. 9 about the state of play as the end of the year neared.
